Is Abeona Therapeutics Stock a Good Investment?
Abeona Therapeutics Investment Advice | ABEO |
- Examine Abeona Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Abeona Therapeutics' leadership team and their track record. Good management can help Abeona Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Abeona Therapeutics' business and its evolving consumer preferences.
- Compare Abeona Therapeutics' performance and market position to its competitors. Analyze how Abeona Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Abeona Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Abeona Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Abeona Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Abeona Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Abeona Therapeutics Stock
Researching Abeona Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 76.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.05. Abeona Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 5th of July 2022.
To determine if Abeona Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Abeona Therapeutics' research are outlined below:
| The company reported the previous year's revenue of 3.5 M. Net Loss for the year was (54.19 M) with loss before overhead, payroll, taxes, and interest of (31.4 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (37.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Abeona Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Omalley Brendan M. of 5869 shares of Abeona Therapeutics at 3.13 subject to Rule 16b-3 |
Abeona Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Abeona Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abeona Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Abeona Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Abeona Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.4 | -0.3143 | 0.0857 | 21 | ||
2022-08-11 | 2022-06-30 | -1.87 | -2.08 | -0.21 | 11 | ||
2023-08-08 | 2023-06-30 | -0.68 | -0.92 | -0.24 | 35 | ||
2022-11-14 | 2022-09-30 | -1.75 | -1.48 | 0.27 | 15 | ||
2024-03-18 | 2023-12-31 | -0.47 | -0.77 | -0.3 | 63 | ||
2017-05-15 | 2017-03-31 | -3.75 | -3.25 | 0.5 | 13 | ||
2024-08-12 | 2024-06-30 | -0.36 | 0.19 | 0.55 | 152 | ||
2024-05-15 | 2024-03-31 | -0.51 | -1.16 | -0.65 | 127 |
Know Abeona Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Abeona Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abeona Therapeutics backward and forwards among themselves. Abeona Therapeutics' institutional investor refers to the entity that pools money to purchase Abeona Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Propel Bio Management Llc | 2024-09-30 | 624 K | Citigroup Inc | 2024-09-30 | 616.7 K | Ikarian Capital, Llc | 2024-12-31 | 533.6 K | Blackrock Inc | 2024-09-30 | 479.6 K | Geode Capital Management, Llc | 2024-09-30 | 465.3 K | Simplify Asset Management Inc. | 2024-12-31 | 408.6 K | Newtyn Management Llc | 2024-09-30 | 380 K | Bank Of America Corp | 2024-09-30 | 226.7 K | Abrdn Plc | 2024-12-31 | 224.4 K | Suvretta Capital Management, Llc | 2024-12-31 | 3.7 M | Nantahala Capital Management, Llc | 2024-09-30 | 3.4 M |
Abeona Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 262.43 M.Market Cap |
|
Abeona Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (0.80) | |
| Return On Capital Employed | (0.84) | (0.80) | |
| Return On Assets | (0.76) | (0.80) | |
| Return On Equity | (3.29) | (3.45) |
Determining Abeona Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Abeona Therapeutics is a good buy. For example, gross profit margin measures Abeona Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Abeona Therapeutics' profitability and make more informed investment decisions.
Evaluate Abeona Therapeutics' management efficiency
Abeona Therapeutics has return on total asset (ROA) of (0.4068) % which means that it has lost $0.4068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.095) %, meaning that it created substantial loss on money invested by shareholders. Abeona Therapeutics' management efficiency ratios could be used to measure how well Abeona Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2025, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to grow to -0.8. At this time, Abeona Therapeutics' Other Current Assets are very stable compared to the past year. As of the 17th of February 2025, Non Current Assets Total is likely to grow to about 17.3 M, while Total Assets are likely to drop about 49.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.80 | 0.76 | |
| Tangible Book Value Per Share | 0.80 | 0.76 | |
| Enterprise Value Over EBITDA | (1.74) | (1.83) | |
| Price Book Value Ratio | 8.31 | 8.72 | |
| Enterprise Value Multiple | (1.74) | (1.83) | |
| Price Fair Value | 8.31 | 8.72 | |
| Enterprise Value | 88.2 M | 94.4 M |
Abeona Therapeutics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta 1.425 |
Basic technical analysis of Abeona Stock
As of the 17th of February 2025, Abeona Therapeutics shows the risk adjusted performance of (0.01), and Mean Deviation of 1.7. Abeona Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Abeona Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abeona Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abeona Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abeona Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Abeona Therapeutics' Outstanding Corporate Bonds
Abeona Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Abeona Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Abeona bonds can be classified according to their maturity, which is the date when Abeona Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ABBOTT LABS 295 Corp BondUS002824BB55 | View | |
| ABBOTT LABS 6 Corp BondUS002824AV29 | View | |
| ABBOTT LABS 53 Corp BondUS002824AY67 | View | |
| US002824BP42 Corp BondUS002824BP42 | View | |
| US002824BQ25 Corp BondUS002824BQ25 | View | |
| ABBOTT LABS 475 Corp BondUS002824BG43 | View | |
| US002824BF69 Corp BondUS002824BF69 | View | |
| ABBOTT LABS 49 Corp BondUS002824BH26 | View |
Understand Abeona Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Abeona Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 1.7 | |||
| Coefficient Of Variation | (4,562) | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.0 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.07) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 15.57 | |||
| Value At Risk | (4.25) | |||
| Potential Upside | 6.1 | |||
| Skewness | (0.21) | |||
| Kurtosis | 2.95 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 1.7 | |||
| Coefficient Of Variation | (4,562) | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.0 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.07) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 15.57 | |||
| Value At Risk | (4.25) | |||
| Potential Upside | 6.1 | |||
| Skewness | (0.21) | |||
| Kurtosis | 2.95 |
Consider Abeona Therapeutics' intraday indicators
Abeona Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abeona Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Abeona Therapeutics Corporate Filings
F4 | 3rd of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 6th of January 2025 Other Reports | ViewVerify | |
8K | 20th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of November 2024 Other Reports | ViewVerify |
Abeona Stock media impact
Far too much social signal, news, headlines, and media speculation about Abeona Therapeutics that are available to investors today. That information is available publicly through Abeona media outlets and privately through word of mouth or via Abeona internal channels. However, regardless of the origin, that massive amount of Abeona data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Abeona Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Abeona Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Abeona Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Abeona Therapeutics alpha.
Abeona Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Abeona Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Abeona Therapeutics Corporate Management
| Joseph Vazzano | Chief Officer | Profile | |
| Dmitriy MD | Chief Officer | Profile | |
| Brian Kevany | CTO VP | Profile | |
| Carl Denny | Senior Affairs | Profile | |
| Alison Hardgrove | Vice Resources | Profile | |
| Scott Santiamo | Director Communications | Profile |
Already Invested in Abeona Therapeutics?
The danger of trading Abeona Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abeona Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abeona Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abeona Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Abeona Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.